Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib - PubMed (original) (raw)
Meta-Analysis
. 2001 Nov 6;104(19):2280-8.
doi: 10.1161/hc4401.100078.
Affiliations
- PMID: 11696466
- DOI: 10.1161/hc4401.100078
Meta-Analysis
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
M A Konstam et al. Circulation. 2001.
Abstract
Background: In comparing aspirin, nonselective nonsteroidal antiinflammatory agents (NSAIDs), and cyclooxygenase (COX)-2 inhibitors, variation in platelet inhibitory effects exists that may be associated with differential risks of cardiovascular (CV) thrombotic events. Among the randomized, controlled trials with the COX-2 inhibitor rofecoxib, one study demonstrated a significant difference between rofecoxib and its NSAID comparator (naproxen) in the risk of CV thrombotic events. A combined analysis of individual patient data was undertaken to determine whether there was an excess of CV thrombotic events in patients treated with rofecoxib compared with those treated with placebo or nonselective NSAIDs.
Methods and results: CV thrombotic events were assessed across 23 phase IIb to V rofecoxib studies. Comparisons were made between patients taking rofecoxib and those taking either placebo, naproxen (an NSAID with near-complete inhibition of platelet function throughout its dosing interval), or another nonselective NSAIDs used in the development program (diclofenac, ibuprofen, and nabumetone). The major outcome measure was the combined end point used by the Antiplatelet Trialists' Collaboration, which includes CV, hemorrhagic, and unknown deaths; nonfatal myocardial infarctions; and nonfatal strokes. More than 28 000 patients, representing >14 000 patient-years at risk, were analyzed. The relative risk for an end point was 0.84 (95% CI: 0.51, 1.38) when comparing rofecoxib with placebo; 0.79 (95% CI: 0.40, 1.55) when comparing rofecoxib with non-naproxen NSAIDs; and 1.69 (95% CI: 1.07, 2.69) when comparing rofecoxib with naproxen.
Conclusions: This analysis provides no evidence for an excess of CV events for rofecoxib relative to either placebo or the non-naproxen NSAIDs that were studied. Differences observed between rofecoxib and naproxen are likely the result of the antiplatelet effects of the latter agent.
Comment in
- Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Jaeschke R, Gajewski P, Brozek J. Jaeschke R, et al. Circulation. 2002 Jul 30;106(5):e18. doi: 10.1161/01.cir.0000023454.92028.12. Circulation. 2002. PMID: 12147551 No abstract available.
Similar articles
- Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR, Sperling RS, Reicin A, Gertz BJ. Weir MR, et al. Am Heart J. 2003 Oct;146(4):591-604. doi: 10.1016/S0002-8703(03)00398-3. Am Heart J. 2003. PMID: 14564311 Review. - Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ; Alzheimer's Disease Cooperative Study. Aisen PS, et al. JAMA. 2003 Jun 4;289(21):2819-26. doi: 10.1001/jama.289.21.2819. JAMA. 2003. PMID: 12783912 Clinical Trial. - Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Watson DJ, et al. Arch Intern Med. 2000 Oct 23;160(19):2998-3003. doi: 10.1001/archinte.160.19.2998. Arch Intern Med. 2000. PMID: 11041909 - Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ. Matchaba P, et al. Clin Ther. 2005 Aug;27(8):1196-214. doi: 10.1016/j.clinthera.2005.07.019. Clin Ther. 2005. PMID: 16199245 Review.
Cited by
- Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis.
Kurth T, Hennekens CH, Buring JE, Gaziano JM. Kurth T, et al. Curr Rheumatol Rep. 2004 Oct;6(5):351-6. doi: 10.1007/s11926-004-0009-0. Curr Rheumatol Rep. 2004. PMID: 15355747 Review. - Cardiovascular risk, hypertension, and NSAIDs.
White WB. White WB. Curr Pain Headache Rep. 2007 Dec;11(6):428-35. doi: 10.1007/s11916-007-0229-x. Curr Pain Headache Rep. 2007. PMID: 18173977 Review. - Cyclooxygenase-1 and prostacyclin production by endothelial cells in the presence of mild oxidative stress.
Toniolo A, Buccellati C, Pinna C, Gaion RM, Sala A, Bolego C. Toniolo A, et al. PLoS One. 2013;8(2):e56683. doi: 10.1371/journal.pone.0056683. Epub 2013 Feb 18. PLoS One. 2013. PMID: 23441213 Free PMC article. - Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005.
Patel H, Bell D, Molokhia M, Srishanmuganathan J, Patel M, Car J, Majeed A. Patel H, et al. BMC Clin Pharmacol. 2007 Sep 25;7:9. doi: 10.1186/1472-6904-7-9. BMC Clin Pharmacol. 2007. PMID: 17894876 Free PMC article. - [Therapy with nonsteroidal anti-inflammatory drugs].
Bauer H, Märker-Hermann E. Bauer H, et al. Orthopade. 2003 Dec;32(12):1088-94. doi: 10.1007/s00132-003-0559-2. Orthopade. 2003. PMID: 14655005 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials